Ming-Kuei Jang, founder and CEO of Aprinoia, a very promising Taiwan-based company focused on the development of groundbreaking imaging tracers and therapeutics targeting tau-related neurodegenerative diseases, provides insights into the company’s rapid development over the past two years, its R&D strategy, and its eagerness to partner with both academia and the industry to bring life-changing and affordable products to CNS patients around the world.
Could you walk us through the main milestones of your career that led to the creation of Aprinoia in May 2015?
"We are following a different strategy than most companies involved in the CNS field – an area that has remained desperately static in recent decades, despite dramatic unmet needs."
